Thank you very much for your interest in participating in this short survey !
Why is the survey being conducted?
The purpose of this survey is to better understand patient and caregiver perspectives regarding clinical trial information, awareness, navigation and access.
The data gathered will be used by argenx and by patient organizations to co-create innovative solutions to improve patient awareness and access to clinical trials.
At the conclusion of the survey, there will be an optional question concerning patient preferences for the dosing of a potential future treatment. Your input will help ensure that this treatment aligns with patient requirements.
Why take part?
Participation in this survey will provide direct insights from patients and caregivers on clinical trial awareness and access. These insights will be used to create innovative solutions which will potentially make it easier for people like you to find and access to clinical trials.
Also, answers to the last question on dosing will help design a potential treatment matching patient preferences.
How long does it take to complete this survey?
The following anonymous online survey will take less than 15 minutes to complete.
Who can take part to this survey?
Adults living with these diseases or their caregiver:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Guillain‑Barré Syndrome (GBS)
- Multifocal Motor Neuropathy (MMN).
Who is organising the survey?
This survey has been initiated and funded by argenx and admedicum is conducting this research project on behalf of argenx.
argenx is a global biopharma company developing innovative therapies to treat severe autoimmune diseases.
admedicum is a company committed to improving the healthcare systems and taking better account of the needs of patients.
Thank you for participating in this survey and making a difference for people living with CIDP, GBS and MMN.
CA - MED - LO - 0051
